60 Degrees Pharmaceuticals Inc - Understand $sxtp stock

$SXTP Market Cap: $2.078 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$335.3K

TTM

Gross Margin

-52.35%

TTM

Net Earnings

-$1.691M

TTM

Current Assets

$3.763M

Q2 2024

Current Liabilities

$1.219M

Q2 2024

Current Ratio

308.66%

Q2 2024

Total Assets

$4.327M

Q2 2024

Total Liabilities

$1.368M

Q2 2024

Book Value

$2.959M

Q2 2024

Cash

$1.577M

Q2 2024

P/E

-1.229

Oct 16, 2024 EST

Free Cash Flow

-$6.380M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020
Revenue	$253.6K	$511.2K	$6.353M	$2.181M
YoY Change	-50.4%	-91.95%	191.23%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020
Revenue	$253.6K	$511.2K	$6.353M	$2.181M
Cost Of Revenue	$474.6K	$432.4K	$850.7K	$703.0K
Gross Profit	-$221.0K	$78.84K	$5.502M	$1.478M
Gross Profit Margin	-87.15%	15.42%	86.61%	67.77%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020
Selling, General & Admin	$4.242M	$1.304M	$1.115M	$1.458M
YoY Change	225.36%	16.89%	-23.5%
% of Gross Profit		1653.63%	20.27%	98.62%
Research & Development	$691.8K	$525.6K	$5.511M	$806.7K
YoY Change	31.63%	-90.46%	583.15%
% of Gross Profit		666.62%	100.16%	54.57%
Depreciation & Amortization	$50.32K	$32.77K	$30.84K	$27.87K
YoY Change	53.56%	6.26%	10.66%
% of Gross Profit		41.57%	0.56%	1.89%
Operating Expenses	$4.934M	$1.829M	$6.626M	$2.265M
YoY Change	169.7%	-72.39%	192.6%
Operating Profit	-$5.155M	-$1.750M	-$1.124M	-$786.2K
YoY Change	194.47%	55.72%	42.97%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020
Interest Expense	-$2.724M	-$4.504M	-$3.173M	-$2.629M
YoY Change	-39.53%	41.97%	20.67%
% of Operating Profit
Other Income/Expense, Net	$5.296M	-$43.24K	$37.52K	$368.1K
YoY Change	-12348.27%	-215.25%	-89.81%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020
Pretax Income	-$3.814M	-$6.177M	-$4.259M	-$3.047M
YoY Change	-38.26%	45.03%	39.77%
Income Tax	$250.00	$500.00	$1.000K	$1.000K
% Of Pretax Income
Net Earnings	-$3.986M	-$6.182M	-$4.252M	-$3.034M
YoY Change	-35.51%	45.39%	40.15%
Net Earnings / Revenue	-1572.12%	-1209.23%	-66.93%	-139.08%
Basic Earnings Per Share	-$0.99	-$2.61
Diluted Earnings Per Share	-$1.01	-$1.11	-$0.76	-$0.54

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020
Cash & Short-Term Investments	$2.142M	$264.9K	$115.4K	$191.7K
YoY Change	708.88%	129.52%	-39.8%
Cash & Equivalents	$2.142M	$264.9K	$115.4K	$191.7K
Short-Term Investments
Other Short-Term Assets	$4.403M	$269.6K	$225.9K	$352.2K
YoY Change	1533.01%	19.36%	-35.86%
Inventory	$466.2K	$518.6K	$689.0K	$1.040M
Prepaid Expenses
Receivables	$231.3K	$45.97K	$146.4K	$859.4K
Other Receivables	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.243M	$1.099M	$1.177M	$2.443M
YoY Change	559.02%	-6.6%	-51.83%
Property, Plant & Equipment	$71.28K	$33.95K	$107.6K	$73.41K
YoY Change	109.96%	-68.45%	46.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$242.7K			$9.550K
YoY Change
Total Long-Term Assets	$541.2K	$198.2K	$216.9K	$163.2K
YoY Change	173.03%	-8.6%	32.9%
Total Assets	$7.784M	$1.297M	$1.394M	$2.606M
YoY Change
Accounts Payable	$506.2K	$758.7K	$588.7K	$1.377M
YoY Change	-33.28%	28.88%	-57.25%
Accrued Expenses	$13.65K	$13.00K	$46.80K	$0.00
YoY Change	5.0%	-72.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.770K	$21.33M
YoY Change	-99.96%
Total Short-Term Liabilities	$2.835M	$23.92M	$635.5K	$1.433M
YoY Change	-88.15%	3664.33%	-55.67%
Long-Term Debt	$150.3K	$1.270M	$18.74M	$19.14M
YoY Change	-88.17%	-93.22%	-2.07%
Other Long-Term Liabilities	$0.00	$255.0K	$167.7K	$103.0K
YoY Change	-100.0%	52.02%	62.84%
Total Long-Term Liabilities	$150.3K	$1.525M	$18.91M	$19.24M
YoY Change	-90.15%	-91.94%	-1.72%
Total Liabilities	$2.914M	$24.87M	$18.97M	$20.11M
YoY Change	-88.29%	31.11%	-5.65%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022
Basic Shares Outstanding	3.960M shares	2.368M shares
Diluted Shares Outstanding	3.960M shares	2.368M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.0779 Million

About 60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 2 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Industry: Pharmaceutical Preparations Peers: DMK Pharmaceuticals Corp Avenue Therapeutics Inc CNS Pharmaceuticals Inc Eli Lilly and Co Eloxx Pharmaceuticals Inc Processa Pharmaceuticals Inc Hoth Therapeutics Inc PaxMedica Inc Pulmatrix Inc Virpax Pharmaceuticals Inc